Skip to main content
. 2021 May 1;527:111220. doi: 10.1016/j.mce.2021.111220

Fig. 2.

Fig. 2

Characterization of AKR1C2 and AKR1C3 expression in the stroma vascular fraction of adipose tissue at the single-cell level. AKR1C2 and AKR1C3 expression in subcutaneous (SAT) and visceral (VAT), all cells combined. Expression (mean ± SD): AKR1C2 SAT: 2.73 ± 0.48; VAT: 2.67 ± 0.72; AKR1C3 SAT: 2.71 ± 0.52; VAT: 2.86 ± 0.60 (A); in subcutaneous clusters of the stroma vascular fraction (B), SP1and SP3: adipocyte progenitor cells (APCs), mean ± SD expression SP1: AKR1C2 2.02 ± 0.69; AKR1C3 1.96 ± 0.76; SP3: AKR1C2 1.46 ± 0.39; AKR1C3 2.26 ± 0.70), SP2: adipocyte-committed APCs (mean AKR1C2 expression 2.09 ± 0.85; mean AKR1C3 expression 2.1 ± 0.89), SP4: fibroblasts (mean AKR1C2 expression 2.5 ± 0.69; mean AKR1C3 expression 2.25 ± 0.70), SP5: hematopoietic stem cell progenitors (mean AKR1C2 expression 1.66 ± 0.4; mean AKR1C3 expression 1.70 ± 0.53); percent of cells expressing and average expression of AKR1C2 and AKR1C3 in the different subcutaneous clusters (C).